Program Goals

Click here to register for this event

The purpose of this activity is to educate participants on the use of integrase inhibitors in clinical practice, and the differential risk associated with the patterns of integrase resistance observed. Integrase inhibitor(s) cross-resistance and available testing options for both genotypic and phenotypic drug susceptibility will be discussed.

Target Audience

Infectious Disease physicians, virologists, HIV specialists, clinical laboratory and other healthcare professionals interested in the management of HIV patients.

Educational Objectives

Upon completion of this activity, participants should be able to:

  1. Recall the clinical trials and resulting data on raltegravir and investigational integrase inhibitors including risk of resistance emergence in different trial settings.
  2. Review the mechanisms and clinical consequences of integrase inhibitor drug resistance and the potential for cross resistance among integrase inhibitors.
  3. Explain laboratory testing options for monitoring integrase inhibitor resistance.

Faculty

Joseph J. Eron, Jr., MD
Professor of Medicine
University of North Carolina School of Medicine
Principal Investigator HIV/AIDS Clinical Research Unit
University of North Carolina
Chapel Hill, NC

Agenda

- 05 minutes: Welcome & Introduction
- 40 minutes: Faculty Presentation
- 10 minutes: Question & Answer Session
- 05 minutes: Evaluation & Post Test

 

Disclosure of Conflicts of Interests

Dane Garvin Ltd. (DGL) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted for fair balance, scientifice objectivity, and appropriateness of content.

Faculty Disclosures

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.® accredited activity:

 

Name Type Commercial Supporter
Joseph J. Eron, Jr., MD









Grant / Research Support

Glaxo Smith Kline/ViiV; Merck & Co., Inc.;
TaiMed. 
Consultant



Avexa Ltd.; Bristol-Myers Squibb
Company; Chimerix Inc.; GSK/ViiV; Merck
& Co., Inc; Pfizer Inc.; Tibotec Pharmaceuticals;
Tobira Therapeutics; Virco Laboratories; Gilead Sciences, Inc.; Myriad; Inhibitex; Argos.
Speakers' Bureau


Bristol-Myers Squibb Company; Roche Pharmaceuticals; Virco Laboratories.

Planners and Managers

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.® accredited activity:

 

ASCLS - Name of Planner or Manager Reported Financial Relationship
Nothing to disclose Nothing to disclose
DGL - Name of Planner or Manager Reported Financial Relationship
LaRue Highsmith Nothing to disclose
(Spouse - no planning role) Admin: Abbott Laboratories

Credit Designation - Lab Professional, P.A.C.E.®

The American Society for Clinical Laboratory Science's Professional Acknowledgment for Continuing Education (P.A.C.E.®) Program will provide 1.0 contact hour of credit.

How to Obtain P.A.C.E.® Credit

ACCREDITATION FOR THIS ACTIVITY HAS EXPIRED

PACE_Logo.jpgViewers are expected to complete the presentation before attempting to submit contact information and the session evaluation. Successful completion will lead to the issuance of a certificate for 1.0 contact hour of P.A.C.E.® approved continuing education. To receive credit, the course must be completed by October 1, 2012.

Participation in this activity should be completed in approximately 1 hours. Please follow these steps in order to receive P.A.C.E.® credit for viewing the webcast: 

  • Read all of the information above.
  • View the complete webcast program.
  • Click on the "Lab Professional" link to apply for P.A.C.E.® credit.
  • Complete the online registration (registration is free).
  • Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive P.A.C.E.® credit.
  • After successful completion of this process, you will be redirected to the ASCLS CE Organizer where you may create and print an official ASCLS P.A.C.E.® certificate based on your attendance and completion of this ASCLS-sponsored P.A.C.E.® approved learning activity.

 Should you have any P.A.C.E.® questions regarding this activity, please contact:

ASCLS P.A.C.E.®
1861 International Drive, Suite 200
Tysons Corner, VA 22102
Ph: 571-748-3776
Fx: 571-354-7576
https://www.ascls.org/

For technical difficulties, please consult our Technical Instructions.

Release and Expiration

Enduring Archive Release date: October 1, 2011

Enduring Archive Expiration date: October 1, 2012

 

Fee Information

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Society for Clinical Laboratory Science (ASCLS) and Dane Garvin Ltd. (DGL) do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Policy on Privacy and Confidentiality

Dane Garvin Ltd. (DGL) protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. DGL and our educational joint sponsors will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Dane Garvin Ltd. and the American Society for Clinical Laboratory Science maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Legal Disclaimer

The opinions expressed in this educational activity are those of the faculty and do not reflect the views of Dane Garvin Ltd. and/or the American Society for Clinical Laboratory Science. This educational activity may discuss off-label and/or investigational uses and dosages for therapeutic products/procedures that have not been approved by the United States Food and Drug Administration (FDA). Dane Garvin Ltd. and the American Society for Clinical Laboratory Science do not recommend the use of any product/procedure outside of the labeled indications. A qualified health care professional should be consulted before using any therapeutic product/procedure discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity. Please refer to the official prescribing information for each product/procedures for approved indication, contraindications, and warnings.

Medium Used

This program has been made available online.

"Integrase Inhibitor Drug Resistance in Clinical Practice"

System Requirements

To view this educational activity you will need a web browser with Javascript and either Flash or HTML5 enabled.  Nearly all modern web browsers will work.

Cosponsor

AMPlogo_transp_150.gif   This activity is co-sponsored by the Association for Molecular Pathology.

Commercial Support Statement

Abbott_logo.png    This activity supported by an educational grant from Abbott Molecular.

Copyright

Copyright © October 1, 2011 - October 1, 2012.  Dane Garvin, Ltd.   All Rights Reserved.   Permission for accreditation is granted to the American Society for Clinical Laboratory Science.